HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the appointment of Niv Ad, M.D. as Chief Science Officer, Cardiac Surgery..

加利福尼亚州海沃德（BUSINESS WIRE）-Pulse Biosciences，Inc。（纳斯达克股票代码：PLSE，“该公司”）是一家主要致力于利用其新颖专有的纳秒脉冲场消融（nsPFA）技术治疗心房颤动的公司，今天宣布任命Niv Ad，医学博士为心脏外科首席科学官。。

“After working with the Pulse Biosciences’ team and participating in preclinical studies using the nsPFA clamp for cardiac ablation, it was immediately clear to me that nsPFA has the potential to not only replace all other energy modalities in cardiac ablation, including radiofrequency and cryo, but due to the speed, safety, and ablation performance of the system, it has the potential to significantly expand the number of patients we treat in cardiac surgery,” said Dr.

“在与Pulse Biosciences团队合作并参与使用nsPFA钳夹进行心脏消融的临床前研究后，我立即清楚地看到，nsPFA不仅可以取代心脏消融中的所有其他能量模式，包括射频和冷冻，但由于系统的速度，安全性和消融性能，它有可能签署博士说，大大扩大了我们在心脏手术中治疗的患者人数。

Niv Ad, Chief Science Officer, Cardiac Surgery. “Because of this and how far along the Company is in the development of a commercially viable system, I decided to join this experienced team as it enters this next exciting phase of bringing nsPFA from the lab to the clinic to make a positive impact on patient lives and healthcare.

Niv Ad，心脏外科首席科学官。“由于这一点以及公司在开发商业上可行的系统方面有多远，我决定加入这个经验丰富的团队，因为它进入了将nsPFA从实验室带到诊所的下一个令人兴奋的阶段，从而对患者产生积极影响生活和医疗保健。

I look forward to working alongside this impressive team.”.

我期待着与这个令人印象深刻的团队合作。”。

Dr. Ad is a leading authority in surgical treatment of atrial fibrillation, minimally invasive heart surgery and other advanced heart surgery techniques and transcatheter therapies. Dr. Ad has published more than 200 research articles in peer-reviewed publications. He has led the development of national and international clinical practice guidelines for the different cardiovascular societies for ISMICS, AATS and STS, and serves on multiple leadership positions and committees in the leading cardiothoracic societies.

Ad博士是心房颤动手术治疗，微创心脏手术和其他先进心脏手术技术和经导管治疗的领先权威。Ad博士在同行评审的出版物中发表了200多篇研究文章。他领导了针对ISMICS，AATS和STS的不同心血管学会的国家和国际临床实践指南的制定，并在领先的心胸学会担任多个领导职位和委员会成员。

He is the past president of The International Society of Minimally Invasive Cardiothoracic and Vascular Surgery (MICS), the leading entity for minimally invasive procedures globally and he is the Editor in Chief of INNOVATIONS: Technology and Techniques in Cardiothoracic and Vascular Surgery..

他是国际微创心胸血管外科学会（MICS）的前任主席，MICS是全球微创手术的领先实体，也是心胸血管外科技术创新主编。。

“We are excited to have Dr. Ad join the Pulse Biosciences team. His proven track record and expertise will play an integral role in not only our clinical strategy and driving awareness of our technology through scientific data dissemination, but also contributing to the development of our product portfolio for cardiac surgery,” said Kevin Danahy, Chief Executive Officer of Pulse Biosciences.

“我们很高兴让Ad博士加入Pulse生物科学团队，他久经考验的记录和专业知识将不仅在我们的临床战略和通过科学数据传播推动我们技术意识方面发挥不可或缺的作用，而且还有助于发展我们的心脏外科产品组合，“Pulse生物科学首席执行官Kevin Danahy说。

“We believe two of the top cardiothoracic surgeons in the world, Dr. Niv Ad and Dr. Gansevoort ‘Gan’ Dunnington, committing to join our leadership team after firsthand experience with nsPFA validates our scientific and engineering expertise and is indicative of strong future market adoption of our technology.”.

“我们相信世界上两位心胸外科医生，Niv Ad博士和Gansevoort'Gan'Dunnington博士，在与nsPFA的第一手经验验证了我们的科学和工程专业知识后，承诺加入我们的领导团队，这表明我们的技术未来市场应用强劲“。

About Pulse Biosciences®

关于PulseBiosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue.

Pulse Biosciences是一家致力于健康创新的新型生物医药公司，有可能改善患者的生活质量。该公司专有的纳秒脉冲场消融（nsPFA）技术可将纳秒电能脉冲提供给非热透明细胞，同时保留相邻的非细胞组织。

The Company is actively pursuing the development of its nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where nsPFA could have a profound positive impact on healthcare for both patients and providers..

该公司正在积极开发其nsPFA技术，用于治疗心房颤动以及其他一些市场，nsPFA可对患者和医疗服务提供者的医疗保健产生深远的积极影响。。

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Pulse Biosciences，CellFX，Nano Pulse Stimulation，NPS，nsPFA和程式化徽标是Pulse Biosciences，Inc.在美国和其他国家/地区的商标和/或注册商标。

Forward-Looking Statements

前瞻性声明

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to statements concerning the effectiveness of the Company’s nsPFA technology and CellFX System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company’s expected product development efforts, statements concerning customer adoption and future use of the CellFX System to address a range of conditions such as atrial fibrillation, and Pulse Biosciences’ expectations, whether stated or implied, regarding whether the Company’s nsPFA technology will become a disruptive treatment option for treating cardiac arrhythmias and whether future clinical studies will show the CellFX System is safe and effective to treat atrial fibrillation or any other medical condition, and other future events.

本新闻稿中所有非历史性的陈述都是前瞻性陈述，其中包括有关公司nsPFA技术和CellFX系统对非热透明细胞有效性的陈述，同时保留相邻的非细胞组织，关于公司预期产品开发工作的陈述，关于客户采用和未来使用CellFX系统来解决一系列条件（如心房颤动）和Pulse Biosciences的期望（无论是陈述还是暗示）的陈述，关于公司的nsPFA技术是否将成为治疗心律失常的颠覆性治疗选择，以及未来的临床研究是否会显示CellFX系统对于治疗心房颤动或任何其他疾病以及其他未来事件是安全有效的。

These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words.

这些陈述不是历史事实，而是基于Pulse Biosciences当前对Pulse Biosciences业务，运营和其他类似或相关因素的期望，估计和预测。诸如“可能”，“将会”，“可以”，“将会”，“应该”，“预期”，“预测”，“潜力”，“继续”，“期望”，“意图”，“计划”，“项目”，“相信”，“估计”以及其他类似或相关的表达方式用于识别这些前瞻性陈述，尽管并非所有前瞻性陈述都包含这些词语。

You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors.

您不应该过分依赖前瞻性陈述，因为它们涉及已知和未知的风险，不确定性以及难以或不可能预测的假设，并且在某些情况下超出Pulse Biosciences的控制范围。由于许多因素，实际结果可能与前瞻性陈述中的结果大不相同。